Drug class or analogue
Amylin Analogue
A class of amylin-receptor agonists that slow gastric emptying, suppress post-meal glucagon and increase satiety. Evidence and regulatory status vary substantially by molecule.
Evidence confidence
Human
5/5
Strong human clinical evidence
4 citations
Animal
Not yet assessed
Trust Engine review pending.
Mechanistic
Not yet assessed
Trust Engine review pending — see editorial links below.
Editorial evidence links exist, but this category has not yet completed Trust Engine assessment.
Safety
3/5
Reasonable safety characterisation
3 citations
Claimed uses
- Moderate
- Strong
Mechanisms
- not-yet-documented
- Amylin receptor signalling
Safety notes
Nausea is common. Severe hypoglycaemia can occur when used with insulin unless mealtime insulin is appropriately reduced. It can delay absorption of oral medicines and is unsuitable in gastroparesis.
Regulation
- Pramlintide is a licensed prescription medicine in some jurisdictions for selected insulin-treated diabetes populations. Other amylin analogues have separate approval or investigational status.
References
- Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada · 2024
- Pramlintide for post-bariatric hypoglycaemia · 2022
- A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial · 2020
- Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study · 2018
- Pramlintide, the synthetic analogue of amylin · 2008
- The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus · 1999
Last reviewed
11 July 2026